QuantHealth debuts Katina, a new product that helps Pharma researchers run thousands of protocols at scale
The new tool offers researchers and R&D strategists a generative AI approach to holistic decision-making leveraging high-throughput trial protocol simulation
QuantHealth, an AI-powered clinical trial design startup, today announced a major product upgrade to its platform to simulate trials at scale and expedite, de risk and optimize drug development. The new product release, Katina, provides clinical researchers with an AI-guided workflow that simulates hundreds of thousands of potential trial protocol combinations of patient groups, treatment parameters and different endpoints, to maximize the trial success probability, while taking into account additional operational and commercial considerations.
“This release is a game changer for protocol design committees and portfolio optimization teams. Today, these teams facilitate a painstaking negotiation process between the medical, commercial, operational, and regulatory stakeholders, that all need to weigh-in on the pros and cons of each protocol and portfolio decision.”
Post this
“This release is a game changer for protocol design committees and portfolio optimization teams. Today, these teams facilitate a painstaking negotiation process between the medical, commercial, operational, and regulatory stakeholders, that all need to weigh-in on the pros and cons of each protocol and portfolio decision.” said Orr Inbar, Co-Founder and CEO of QuantHealth. “With the power of QuantHealth’s generative AI, and now further enhanced by monte-carlo workflow, the Katina platform fires off thousands of protocols at once and allows each stakeholder to evaluate the simulations based on what matters to them most- be it endpoint success, ability to recruit patients, likelihood of getting an approval, competitive performance, etc. This high-throughput, holistic approach ensures that when it comes to protocol selection and development strategy, no stone is left unturned, and all voices in the room are heard.”
Katina is now integrated into QuantHealth’s platform for clinical trial design, powered by QuantHealths proprietary generative AI that is trained on real-world data from 350 million patients, large biomedical knowledge-graphs, and clinical trial data, and is able to generate synthetic trial data for trial simulation, and boasts endpoint prediction accuracy of 86% for investigational therapies. Katina leverages this proprietary AI technology to test hundreds of thousands of protocols in a simple, easy-to-use search mechanism that allows researchers to select protocols based on AI-generated recommendations or what interests them, drill into each for more information, and compare and contrast them against the standard of care. Upon trial simulation, protocols are assigned different scores and include additional insights based on existing data, to help researchers more easily decide which protocols will work best for their specific trial and disease focus.
This new era of clinical trial optimization, powered by AI and massive real-world patient data, stands to benefit legacy pharmaceutical companies, emerging precision medicine innovators, and patients. Pharmaceutical companies can design better trials for new and existing compounds, and attract and enroll the right patients for a more compelling, data-driven experience. Precision medicine innovators, already using AI to inform drug discovery, can expand upon and digitally validate their ability to select the most responsive patients for trials, helping them market their services to pharmaceutical partners. Ultimately, patients will benefit the most, as more patients will be enrolled in trials that were designed with their real-world experience in mind, and with more precision and accuracy than humans could do alone, improving trial transparency and outcomes.
QuantHealth is already working with several global pharmaceutical companies to use its product in clinical trial design and development. QuantHealth’s latest product innovation comes on the heels of the company raising a $15 million Series A funding round co-led by Bertelsmann Investments and Pitango HealthTech, with participation from existing investors Shoni Top Ventures and Nina Capital.
Source: Business Wire
